Lenzing's EUR 301 Million Is in the Bank; Deutsche Bank Just Halved Its Target Anyway

Lenzing has pencilled in 5 November 2026 for its third-quarter results, giving investors a fixed date to weigh a capital raise that closed roughly two weeks ago against an operating story that has yet to deliver. The financing is complete. The verdict on what it buys the company is not.

The placement pulled in gross proceeds of about EUR 301.2 million through the issue of 34.7 million new shares at EUR 8.65 apiece, with the subscription ratio reaching 99%. Post-raise, Lenzing's share capital stands at EUR 76,204,702.90, divided into 73,374,542 shares, according to the corrected voting-rights notification.

The anchor holders stayed put

The syndicate of B&C Group and Suzano S.A. subscribed 18,159,291 of the new shares and continues to hold roughly 52.25% of voting rights, so the majority bloc survived the dilution intact. Suzano Holding S.A. picked up about 0.80% of Lenzing shares directly, while Goldman Sachs Group was reported at 5.86%. Management also put money in: Georg Kasperkovitz bought shares within the rights offering, and Christian Skilich reported a purchase as well.

That insider participation signals skin in the game. It does not, on its own, certify that the coming restructuring will pay off — a distinction worth keeping in mind as the equity story shifts from balance-sheet repair to execution.

Deutsche Bank draws the line at EUR 12.70

The cautionary counterweight arrived on Wednesday, when Deutsche Bank Research reiterated its "Hold" rating and cut its price target to EUR 12.70 from EUR 22.00. The halving of the target is a reminder that fresh capital does not automatically translate into a higher valuation, and that a large anchor shareholder does not neutralise re-rating risk either. The note offered no breakdown of individual operating assumptions, but the direction was unambiguous.

Against that, the stock rose 3.9% in the prior session. The updated ownership table offers a lens for interpreting that move, not a proven cause of it.

Heiligenkreuz is the real test

The concrete proving ground is the transfer of production out of Heiligenkreuz to other sites. Media reports indicate the planned closure of the plant has been pushed back to the first quarter of 2027 to make that shift possible — a delay that was already a talking point about a week ago. What matters for an investment case now is not another look at the announced window but whether the relocation actually lands inside it. Completing a capital increase and executing a plant transfer are two different tasks, and only one of them is finished.

A confirmed transfer would say more than another announcement about shares already subscribed. Should the relocation slip or prove harder than planned, the gap between a funded balance sheet and operating progress simply persists. The 5 November results will be the next scheduled checkpoint before the Heiligenkreuz clock runs down.

Water, maintenance and the Ager

Operations carry a second, quieter constraint. According to Kronen Zeitung, the site draws cooling and process water from the Ager, and Lenzing has said the strained supply situation is manageable through operational adjustments. Among the options the company cited is bringing forward scheduled maintenance — described as a possibility, not a step already taken.

Pull the threads together and the bull case needs several conditions to align: the raised capital supports delivery, the owners keep backing the course, and the production transfer succeeds. Get all three, and the completed financing becomes a sturdier foundation. The decisive progress would then show up on the factory floor rather than in the shareholder register.